Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid is a synthetic small molecule belonging to the class of biphenyls and derivatives. It is an experimental compound that has been studied as a phosphonate-based inhibitor of matrix metalloproteinases (MMPs), particularly MMP8 (neutrophil collagenase). The compound acts by binding to the active site of MMPs and inhibiting their proteolytic activity. This mechanism suggests potential utility in diseases where excessive matrix degradation by MMPs contributes to pathology, such as cancer metastasis or inflammatory conditions[6][7]. However, there are no approved indications or clinical development programs currently associated with this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid.